Eli Lilly revealed plans this week to invest an additional $450 million in its Research Triangle Park facility in North Carolina.
The expansion will increase the sites parenteral filling, device assembly and packaging capacities to help support the demand for the company’s diabetes products.
In the last three years, Lilly has invested roughly $4 billion into its facilities in North Carolina which includes a $1.7 billion development and expansion of its site at Research Triangle Park. The company anticipates initial production at Research Triangle Park to begin this year, with preparations for inspections by the FDA ongoing.
The site is expected to become fully operational in 2027 and is projected to create at least 100 new manufacturing jobs.
